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IP-10 Levels as an Accurate 
Screening Tool to Detect Acute 
HIV Infection in Resource-Limited 
Settings
Lucía Pastor  1,2,3,4, Aina Casellas1, Jorge Carrillo1,2, Sergi Alonso1,4, Erica Parker5, Laura 
Fuente-Soro1,4, Chenjerai Jairoce4, Inacio Mandomando4, Juli Blanco2,3,6 & Denise Naniche1,4
Acute HIV infection (AHI) is the period prior to seroconversion characterized by high viral replication, 
hyper-transmission potential and commonly, non-specific febrile illness. AHI detection requires 
HIV-RNA viral load (VL) determination, which has very limited access in low-income countries due 
to restrictive costs and implementation constraints. We sought to identify a biomarker that could 
enable AHI diagnosis in scarce-resource settings, and to evaluate the feasibility of its implementation. 
HIV-seronegative adults presenting at the Manhiça District Hospital, Mozambique, with reported-
fever were tested for VL. Plasma levels of 49 inflammatory biomarkers from AHI (n = 61) and non-HIV 
infected outpatients (n = 65) were determined by Luminex and ELISA. IP-10 demonstrated the best 
predictive power for AHI detection (AUC = 0.88 [95%CI 0.80–0.96]). A cut-off value of IP-10 ≥ 161.6 pg/
mL provided a sensitivity of 95.5% (95%CI 85.5–99.5) and a specificity of 76.5% (95%CI 62.5–87.2). 
The implementation of an IP-10 screening test could avert from 21 to 84 new infections and save from 
US$176,609 to US$533,467 to the health system per 1,000 tested patients. We conclude that IP-10 is an 
accurate biomarker to screen febrile HIV-seronegative individuals for subsequent AHI diagnosis with VL. 
Such an algorithm is a cost-effective strategy to prevent disease progression and a substantial number 
of further HIV infections.
Acute HIV infection (AHI) is the period between the acquisition of human immunodeficiency virus (HIV) and 
the development of HIV-specific antibodies that define seroconversion1. AHI is characterised by high HIV viral 
replication and, in most cases, a transient non-specific febrile illness that typically occurs around 2 weeks after 
HIV acquisition1, 2. As a result of high viraemia in bodily fluids and high levels of genital shedding of the virus, 
individuals are considered hyper-infectious during AHI3, 4. In areas of high HIV incidence, this phenomenon 
could contribute greatly to fuelling the worldwide HIV pandemic5.
Despite the importance of early diagnosis and treatment to reduce onward transmissions6, 7 and prevent 
substantial irreversible immunological damage in gut associated lymphoid tissue8, 9, AHI represents a ‘window 
period’ during which persons infected with HIV are commonly undiagnosed1, 10. Routine second generation 
HIV-rapid test algorithms provide negative or indeterminate results for up to 6–8 weeks after infection11. During 
this time, HIV can only be diagnosed by detecting the presence of the virus itself12. The current gold-standard test 
for confirming viraemia is RT-PCR for plasma HIV-RNA11. However, technical and financial constraints make 
this technique very limited in low-income areas1 such as Sub-Saharan Africa (SSA), where the prevalence of AHI 
among febrile patients may reach 3%13–15.
As viraemia increases during AHI, there is a striking cascade response of inflammatory cytokines2. Significant 
efforts have been made to characterise host and viral proteins present during AHI aiming to identify biomarkers 
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of progression or key pathological pathways that could be targeted to minimize HIV-induced immune damage 
over the course of infection2, 16–19. In the present study we sought to determine whether a single or a combination 
of biomarkers could differentiate individuals in AHI from non-HIV infected individuals within a population of 
patients reporting febrile symptoms at a rural hospital in Southern Mozambique. Once plasma level of IP-10 was 
identified as candidate biomarker, we assessed the cost-effectiveness of implementing it for AHI diagnosis in 
low-income settings.
Results
Characteristics of the study population. From the 2748 rapid-test seronegative patients who presented 
at Manhiça District Hospital (MDH) with reported fever during the screening period of the study, 61 (2.2%) were 
identified as AHI. Of the remaining HIV-RNA negative individuals, 65 (2.4%) were randomly selected as non-
HIV-infected individuals with reported fever (NIF). As described in methods, of the 126 AHI and NIF controls, 
95 individuals representing 75% of the study population were used for the model cohort. Median age of the model 
cohort was 23 years (IQR 20–30) and 68% were female. Eleven individuals (12%) had malaria at the moment of 
screening. Median HIV-RNA level in the AHI group was Log10 6.8 copies/mL (IQR 6.1–7.4) and 70.4% patients 
showed a negative Western Blot for HIV-specific antibodies. There were no significant differences in age, gender 
or malaria status by study group (p > 0.1).
Comparison of plasma inflammatory biomarker profile between AHI and non-HIV infected 
febrile controls. From a total of 49 quantifiable biomarkers, the median levels of 24 biomarkers were found 
to significantly differ between AHI and NIF individuals (p-value < 0.05). When comparing normalized bio-
marker levels between AHI and NIF individuals, the AHI group had a higher fold change for all the 24 biomarkers 
except CRP, GCSF, MIP-1alpha, sCD23 and EGF (Fig. 1a). IP-10 and CRP showed the most significant increase in 
the AHI and the NIF groups, respectively (p-value < 0.05). The distribution of the normalized biomarker expres-
sion by study group revealed overlap of interquartile range (IQR) values between AHI and NIF groups for most 
biomarkers; the exceptions being IP-10, MCP-1 and TRAIL (Fig. 1b). When assessing the correlation of the quan-
tifiable biomarkers with the VL levels in the AHI individuals, IP-10 showed the strongest association (rho = 0.6, 
p < 0.0001).
Designing a biomarker-based predictive model for AHI detection. Univariate analysis showed that 
29 of the 49 biomarkers were associated with AHI (p-value < 0.2) and were included in the multivariate analysis. 
A total of 6 cytokines with a p-value < 0.05 were retained in the multivariate model (Table 1). IP-10, sCD14 and 
GMCSF were positively associated with AHI whereas CRP, MIP-1alpha and IL-10 were negatively associated; 
among these, IP-10 showed the strongest association with AHI (p-value = 0.0008).
Of the 29 biomarkers associated with AHI in univariate models, IP-10, TRAIL, BAFF and IL-12 cytokines 
showed the highest predictive power (Area under the curve (AUC) > 0.8) (Fig. 2a), where IP-10 demonstrated 
best accuracy as a single biomarker (AUC = 0.88 [95%CI 0.80–0.96]). Multivariate model adjusted by age, sex 
and malaria infection of the above-mentioned 6 cytokines further increased the classification performance 
(AUC = 0.98 [95%CI 0.96–1.00]) (Fig. 2b). Thus, IP-10 alone and the multivariate 6-cytokine model were identi-
fied as the best classification methods for AHI detection.
Receiver-operating characteristic (ROC) curves of the selected models were used to evaluate several cut-off 
values prioritizing the highest sensitivity (Fig. 2c and d). A cut-off of ≥ 161.6 pg/mL for the univariate IP-10 
model provided a sensitivity of 95.5% (95%CI 85.5–99.5) and a specificity of 76.5% (95%CI 62.5–87.2) (Fig. 2c) 
for predicting AHI. A cut-off score of ≥−0.89 for the multivariate model provided a sensitivity of 97.7% (95%CI 
88.0–99.9) and a specificity of 82% (95%CI 69.1–91.6) (Fig. 2d). Classification performance between the univar-
iate and multivariate methods showed a substantial level of agreement for AHI detection with kappa-statistic of 
0.66 (95%CI 0.51–0.81).
Performance and validation of IP-10 as a single biomarker for AHI identification. Given the 
greater simplicity of implementing a single cytokine assay, the univariate IP-10 model with a cut-off of ≥ 161.6 pg/
mL was assessed for the AHI prevalence observed in the study cohort. We calculated positive and negative pre-
dictive values (PPV and NPV) using model sensitivity and specificity and their respective 95%CIs limits (Fig. 3). 
For an AHI prevalence of 2.2% in HIV-seronegative patients reporting fever, at a specificity of 76.5%, the PPV was 
8.38% (Fig. 3a), and at a sensitivity of 95.5%, the NPV was 99.87% (Fig. 3b).
Using this IP-10 predictive model, 88% of the 17 AHI individuals and 86% of the 14 NIF controls in the val-
idation sample set were correctly classified. These values fell within the 95%CI predicted for the sensitivity and 
specificity of IP-10, thus validating the model prediction power.
Cost-effectiveness analysis of implementing an IP-10 rapid test to screen AHI cases in 
low-income settings. Projecting the observed AHI prevalence of 2.2% in a simulated cohort of 1,000 seron-
egative febrile individuals, 22 individuals would be expected to have AHI. Assuming a high and low transmission 
rate of 1:4 and 1:1, we would expect the 22 AHI to give rise to 88 or to 22 new infections, respectively. In a high 
transmission scenario, lifetime costs of the 110 HIV infections would total US$623,085 (Fig. 4a). In comparison, 
at a low transmission scenario, the mean cost for management of 44 HIV infections would be US$249,234.
The introduction of an IP-10 AHI pre-screening test would include additional costs for IP-10 tests and 
confirmatory VL determinations. With a sensitivity of 95.5%, IP-10 would identify 21 of the 22 AHI with the 
assumption that they would receive ART and thus not transmit the infection. However, 1 AHI would not be 
identified (false negative) and would generate 4 or 1 new infections depending on the transmission rate. For a 
high transmission scenario, the mean cost to the health system for a total of 26 HIV infected individuals would 
be US$89,618 (Fig. 4b) whereas for a low transmission scenario, the mean cost for 23 HIV infected individuals 
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would be US$72,625. Thus, the cost savings are estimated to be US$6,351-8,410 per infection averted. Therefore, 
we estimate that the introduction of an IP-10 pre-screening test would save between US$176,609 and $533,467 
and avert 21–84 new HIV infections per 1000 febrile seronegative outpatients.
Discussion
We have demonstrated that among 49 inflammatory biomarkers assessed, the IP-10 cytokine has the highest 
accuracy in identifying individuals with AHI in a cohort of febrile HIV-seronegative individuals. A cut-off value 
for an IP-10 level of 161.6 pg/mL gave a sensitivity of 95.5% (95%CI 85.5–99.5) and a specificity of 76.5% (95%CI 
62.5–87.2) in identifying AHI, which was confirmed in the validation sample set. The combination of IP-10 
with other biomarkers showed a slightly higher prediction power for AHI detection but a substantial agreement 
was observed for classification performance between IP-10 and the multi-biomarker models. This suggests that 
IP-10 alone may provide a simple and precise way to screen febrile seronegative individuals for subsequent AHI 
diagnosis.
IP-10, also known as CXCL10, is a small cytokine belonging to the CXC chemokine family. IP-10 is produced 
as part of the innate immune response to viruses, bacteria, fungi and parasites20. At the initial stages of HIV 
infection, IP-10 has been shown to greatly increase prior to the development of clinical symptoms paralleling 
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Figure 1. Normalized biomarker levels in AHI and NIF controls. (a) The levels of 24 plasma biomarkers are 
expressed as fold change compared to a reference level (defined in methods) for both AHI and NIF groups. 
Intensity of colour represents biomarker fold change and biomarkers are sorted by fold change value in the AHI 
group. Non-parametric significance of biomarker expression by study group is indicated as *** if P < 0.001,  
** if P < 0.01, and * if P < 0.05. (b) Distribution of the normalized biomarker levels by study group. Results are 
expressed as fold change. Box as IQR, middle line as median, whiskers as Tukey values (1.5*IQR). The orange 
line corresponds to the null change compared to the reference level.
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HIV-VL19. Previous data suggested that IP-10 levels were associated with immune activation21 and predictive 
of rapid disease progression18, 22, representing an earlier biomarker than CD4 T-cell counts or viraemia levels18. 
However, to our knowledge, the strong association between IP-10 and VL levels has not been assessed for its 
ability to identify AHI among seronegative individuals. Our results show that IP-10 can indeed be used to screen 
HIV-seronegative individuals with high predictive ability to differentiate AHI from other patients with undiffer-
entiated fever.
IP-10 has been explored for its use as a prognostic or diagnostic marker for other infectious diseases such as 
malaria, where plasma IP-10 level is associated with fatal cerebral malaria20; hepatitis C, where plasma IP-10 has 
the power to predict liver damage23, or tuberculosis, where IP-10 levels differentiate between active and latent 
tuberculosis irrespective of HIV infection24. Interestingly, high IP-10 levels during HIV infection have been asso-
ciated with increased susceptibility to malaria infection25, however this was not observed in our cohort, and our 
results have not shown an interference of malaria in AHI identification.
Different infections may be distinguished by distinct IP-10 thresholds, but additional research is necessary 
to explore the impact of malaria, tuberculosis and hepatitis C, common HIV comorbidities, on AHI-induced 
levels of IP-10. Parameters such as sensitivity, specificity and cut-off value also need to be optimized expanding 
to other populations affected by different HIV-subtypes or other prevalent co-infections, as well as to non-febrile 
seronegative individuals and pregnant women. Thus, although the IP-10 cut-off value of 161.6 pg/mL provided 
the highest sensitivity in our cohort, it may differ according to context. Importantly, if IP-10 accuracy for AHI 
detection is validated in non-febrile seronegative individuals, this biomarker could also be valuable for screening 
blood donors in low-income countries.
IP-10 is not a disease-specific biomarker20, and its potential use to identify AHI would require a second step 
of confirmation through point of care (POC) VL detection or other HIV-specific detection method. Here we 
suggest the use of IP-10, potentially developed as rapid test, as a pre-screening tool to discriminate AHI from 
other febrile seronegative outpatients in settings of high HIV incidence followed by a POC-VL. IP-10 showed 
a specificity of 76.5%, which would not allow IP-10 to be used as a standalone diagnostic test but represents a 
powerful screening tool to exclude non-HIV infected individuals. Furthermore, at estimated AHI prevalences 
below 5%, the NPV for the IP-10 remains above 99%, thus ensuring that a low number of AHI cases would go 
undiagnosed. In low-income countries, where the cost of individual as well as pooled HIV-VL determinations or 
similar antigen-based assays is prohibitive and the logistics for VL implementation remain highly complex, this 
powerful tool would make AHI screening affordable and feasible, allowing early ART in these individuals and 
preventing a substantial numbers of new HIV infections.
Current practices in Mozambique and similar SSA settings use HIV rapid test serology, which detects infec-
tion from 6 to 8 weeks post-transmission onward, and AHI screening is not conducted. The implementation of 
an IP-10 test to pre-screen febrile seronegative patients could save from 176,609 to 533,467 US$ in treatment and 
diagnostic costs to the health system per 1,000 patients tested, while averting up to 84 new HIV infections. Hence, 
despite the necessity of confirming positive diagnosis with a POC-VL or similar, the introduction of a potential 
IP-10 rapid test as a pre-screening tool would be an important cost-saving strategy compared to leaving AHI undi-
agnosed. We used a public negotiated cost of $16.80 as a POC-VL instead of employing a pooling or individual 
VL strategy because same day return of results has been shown to accelerate ART initiation26. However, for cur-
rent laboratory-based HIV-VL there are major pricing discrepancies across countries27, 28. Recently, MSF reported 
that comprehensive costs including human resources, sample collection, reagents and consumables ranged from 
US$24.90 to 43.42 in the five Sub-Saharan Africa countries surveyed in 2013 (Kenya, Lesotho, Malawi, Swaziland, 
and Zimbabwe)29. We assumed a best case scenario but using these values would increase the cost savings. We 
assumed a cost of an IP-10 rapid test of $1.50 based on commercially available costs for CRP rapid test employed 
in the management of undifferentiated fever30. Both CRP and IP-10 are inflammatory proteins with similar costs 
for detection by ELISA assays purchased at market price. However, the cost-effectiveness model was neither 
probabilistic nor dynamic. Importantly, we disregarded the cost of HIV-associated comorbidities in the simulated 
Variable Coef. (95% Conf. Interval) p-value
Malaria status 3.21 (−0.81; 7.23) 0.1172
Sex
F ref
0.7007
M 0.40 (−1.66; 2.47)
Age −0.03 (−0.12; 0.06) 0.5253
LogIP10 (pg/mL) 5.68 (2.34; 9.01) 0.0008
LogCRP (ug/mL) −1.99 (−3.68; −0.30) 0.0209
LogsCD14 (ug/mL) 14.20 (3.34; 25.07) 0.0104
LogGMCSF (pg/mL) 6.01 (1.44; 10.59) 0.0100
LogMIP1A (pg/mL) −4.59 (−9.12; −0.06) 0.0469
LogIL10 (pg/mL) −5.09 (−9.73; −0.45) 0.0315
Intercept −5.54 (−13.53; 2.45) 0.1743
Table 1. Adjusted multivariate logistic regression of biomarkers associated with AHI. Coefficients per log10 
cytokine unit increment, 95% confidence interval and p-value of the cytokines and confounders that entered 
into the model (p < 0.05) as described in methods.
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cohort which, if included, would most likely increase the cost-effectiveness of the IP-10 followed by POC-VL 
intervention.
Finally, as it has been amply demonstrated, early ART stops progression to AIDS31, 32, diminishes the viral 
reservoir33 and early immunological damage9, as well as reducing further transmissions7. Since the World Health 
Organization updated the HIV recommendations in 201534, many SSA countries are rolling out “test and start” 
programs to initiate ART regardless of CD4 counts. This implies expansion of serological HIV testing strate-
gies but also places AHI detection in the spotlight. Although the development of POC-VL systems has rapidly 
advanced, implementation costs remain elevated. Confronted with the sheer volume of patients requiring VL 
determinations for ART monitoring in many SSA countries, health services will not be able to implement individ-
ual or pooled VL for AHI diagnosis among febrile seronegative outpatients in the near future35. A new approach 
for AHI detection using an affordable IP-10 pre-screening tool to reduce the number of VL determinations nec-
essary by 75%, may be an opportunity to bring AHI diagnosis to low-resource high HIV-burden settings.
In conclusion, we demonstrated that a screening based on IP-10 levels is an accurate and cost-effective strategy 
to detect AHI in HIV-seronegative patients with undifferentiated fever. This algorithm renders AHI diagnosis 
feasible in low-income settings and by treating these individuals a substantial number of progressions to AIDS 
and further HIV transmissions could be averted.
Figure 2. Performance of univariate and multivariate cytokine models in predicting acute HIV infection. 
(a) ROC curves for individual biomarkers with best AHI predictive accuracy (AUC > 0.8). (b) Comparison 
between ROC curves for univariate IP-10 model (AUC = 0.88) and adjusted multivariate biomarker model 
(AUC = 0.98). (c) IP-10 univariate model cut-off points (pg/mL) and (d) multivariate model score cut points 
with their respective sensitivity and specificity values.
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Methods
Study population. The study population was enrolled between 2013 and 2014 at the MDH in Mozambique. 
The present analysis is a sub-study of a prospective cohort of primary HIV-infected adults enrolled15 and followed 
up for 12 months in the Gastro-intestinal biomarkers in AHI Mozambican Adults study (GAMA). This study was 
approved by local institutional review boards at Barcelona Clinic Hospital (2011/6264) and by the Ministry of 
Health of Mozambique (461/CNBS/12). All methods were carried out in accordance with the relevant guidelines 
and regulations. Written informed consent was obtained from patients prior to participation.
HIV diagnosis and biomarker quantification. Technical information and procedures regarding HIV 
diagnosis, clinical follow up, HIV-specific antibody determination and biomarker quantification have been 
previously described15. Individuals presenting to the outpatient clinic of MDH with reported fever, flu-like 
symptoms or malaria suspicion were included in the AHI group of this sub-study if they were HIV-rapid test 
seronegative and HIV-RNA positive. A control population was established by random selection among NIF 
and their screening samples were employed to compare cytokine expression levels with the AHI group. At an 
additional visit, non-febrile HIV-uninfected controls (n = 58) provided samples that were used to establish 
biomarker reference levels in the absence of fever illness15. HIV-specific serology was performed by Western 
Blot. Plasma levels of non-specific antibody isotypes were quantified by an in house ELISA. Multiplex cytokine 
profiling was performed in plasma samples with particular interest in inflammatory cytokines, chemokines, 
hematopoietic factors and biomarkers of intestinal damage. Determinations were performed by ELISA com-
mercial assays or Luminex15.
Statistical analysis. Of the 126 individuals included in this cohort, 75% were used for the data analysis and 
training set (n = 95) and 25% for model validation (n = 31). Proportions were compared using chi-square test. 
Biomarker values were log transformed for a better adjustment of skewed data. In order to normalize biomarker 
levels, fold change was calculated as the ratio of the biomarker level in individuals reporting fever over the median 
value of the non-febrile HIV-uninfected reference group. Distributions of biomarkers in AHI and NIF groups 
were compared by Mann Whitney U-test. Spearman’s correlation was used to assess the strength of relationship 
between continuous variables.
In order to assess the predictive ability of differentially expressed biomarkers to discriminate between AHI 
and NIF individuals, logistic regression with penalized likelihood was performed36. A multivariate model was 
constructed using backward step-wise elimination with an inclusion criterion of p-value < 0.2 in univariate anal-
ysis. Age, gender and malaria infection were retained as potential confounders in the multivariate model because 
of their previous association with alterations in the cytokine expression levels37–39. ROC curves from univariate 
and adjusted-multivariate models were compared for the best prediction40. The level of agreement between the 
classification methods was assessed by the κ-statistic41. Data were analysed using R-3.2.4 software (R Core Team 
2016) and Stata Statistical Software: Release 14 (StataCorp 2015. College Station, TX).
Cost-effectiveness analysis. A deterministic decision analysis was used to estimate the cost-effectiveness 
of introducing a potential IP-10 rapid test to screen febrile HIV-seronegative patients attending a health facility 
compared to current practices in Mozambique, which at present include only HIV antibody-based rapid testing, 
and thus no AHI identification. Health effects and costs to the health care provider associated with HIV/AIDS 
were estimated for a simulated cohort of 1,000 febrile seronegative patients 20 years of age. Economic model 
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Figure 3. AHI Predictive power of the IP-10 model according to prevalence of AHI. (a) Positive predictive 
value (PPV) for varying AHI prevalence estimated for sensitivity = 95.5% and 3 different specificity scenarios 
according to the estimated confidence interval (Sp = 76.5% [95%CI 62.5–87.2]). (b) Negative predictive value 
(NPV) for varying AHI prevalence as estimated for specificity = 76.5% and 3 different sensitivity scenarios 
according to the estimated confidence interval (Se = 95.5% [95%CI 85.5–99.5]).
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outcomes were determined using the AHI prevalence observed in this study and the sensitivity and specificity 
of IP-10 obtained in the univariate model. Health effects were expressed as the number of averted infections. 
Costs per person-year to the health system included: (1) first-line ART drugs and their delivery (assuming com-
plete linkage-to-care); (2) laboratory tests and patient surveillance; and (3) treatment of opportunistic infections 
including tuberculosis prophylaxis42. A unit cost of US$1.50 for a hypothetical IP-10 rapid test was based on 
costs for the CRP rapid test, similarly employed to assist diagnosis among patients with undifferentiated fever30. 
A cartridge-based nucleic acid amplification test (GeneXpert; Cepheid, Sunnyvale, CA, USA) was included as 
a POC-VL confirmation assay with a unit cost of US$16.80, according to FIND negotiated prices for eligible 
countries43. Costs per HIV-infected individual were different between early (CD4 T-cells count > 200) and late 
presenters (CD4 T-cells count =< 200) and both were multiplied by their estimated life expectancy to model 
life-long treatment costs44. Costs were expressed in US$, inflation-adjusted (3%) and discounted (3%). Costs and 
effects were estimated for two different HIV transmission scenarios45. This economic analysis represents a static 
model where transmission only occurs from our cohort of 1,000 individuals to a number (n) of other individuals, 
where n can assume the values of 1 or 4 (low and high transmission scenarios, respectively).
Data Availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
Figure 4. Graphic modelling of the cost-effectiveness analysis. Cost comparison between current practices 
which do not identify AHI (1a) and the implementation of a potential IP-10 rapid pre-screening test (1b) in 
seronegative febrile outpatients for AHI detection in a Sub-Saharan setting.
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